MWVC
RETA

Morgens Waterfall Vintiadis & Co’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,000
Closed -$2.04M – 54
2019
Q4 		$2.04M Buy
+10,000
New +$1.82M 1.39% 28

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's RETA Position: Q3 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 20,000 shares — an estimated $3.12M sold.

Morgens Waterfall Vintiadis & Co first reported a position in RETA in Q2 2018 and held it in 9 quarters. The position peaked at $5.85M in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

  • Morgens Waterfall Vintiadis & Co reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 20,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $3.12M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 9 quarters.
  • Morgens Waterfall Vintiadis & Co's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.85M in Q4 2019.
  • 186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2020, filed 16 Nov 2020.